Fritextsökning
Artiklar per år
Innehållstyper
-
Startup-bolaget vill bli nästa Olink
Inte ens ett år gamla har Rarity Bioscience fått anslag från Swelife och Medtech4health. Nu hoppas vd:n Linus Bosaeus att deras teknik för detektion av mutationer i blodprov hos cancerpatienter ska nå laboratorier redan nästa år.
-
Keyplants får stororder från Galderma
Keyplant ska bygga en life science-anläggning för Galderma i Uppsala, en order som för Keyplant är värd 75 miljoner euro, motsvarande cirka 787 miljoner kronor.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
IVI’s Director General on establishing in Sweden: Will need up to 40 employees
The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Jerome Kim in an interview with Life Science Sweden.
-
Hon blir ny generaldirektör för Vetenskapsrådet
Katarina Bjelke har utsetts till ny generaldirektör och chef för Vetenskapsrådet. Hon tillträder sin nya tjänst den 15 september.
-
The first vaccine derived from cowpox
The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the world’s first smallpox vaccination, and a medical breakthrough had occurred.
-
Nya chefer på Bayer när ny organisation införs i Sverige
Läkemedelsjätten Bayer har utsett Karin Eidolf till Sverigechef för sin läkemedelsdivision, samtidigt som Martin Stagmo blir ny medicinsk chef i Sverige.
-
Now it’s settled: The International Vaccine Institute will be located in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified the agreement, which means that a branch of the institute will be located in Stockholm.
-
The first pharmaceutical for eosinophilic esophagitis approved in the U.S.
The U.S. Drug Administration has approved the drug Dupixent (dupilumab) to treat inflammation of the oesophagus of the type eosinophil esophagitis.
-
No demand for new Covid vaccine – “It will probably be discarded”
So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be discarded due to lack of demand in Sweden as well as globally,” says Sweden’s National Vaccine
-
Företaget som gör apkoppsvaccin: Vi kan producera 30 miljoner doser
Det plötsliga utbrottet av apkoppor gör att ett stort antal länder världen över vill köpa det enda godkända vaccinet mot sjukdomen. Det tillverkas av ett företag i Danmark. – Vi har väldigt mycket att göra nu, konstaterar Rolf Sass Sörensen, Vice President Investor Relations på Bavarian Nordic, till Life Science Sweden.
-
Start-up developing ”digital twin” received award during the EIT Health Summit
A biotech company, a medtech company and a company in digital health were on the podium when the EIT Health Catapult awarded its winners.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.
-
Ingen efterfrågan på nya covidvaccinet – "Måste sannolikt kasseras"
Bara knappt sex tusen doser har hittills getts av covidvaccinet från Novavax i Sverige. Kvar i lager finns över 1,4 miljoner doser. "Det är sannolikt så att de måste kasseras. Det finns ingen efterfrågan, vare sig i Sverige eller globalt", säger Sveriges nationella vaccinsamordnare Richard Bergström till Life Science Sweden.
-
Forskare utvecklar kontaktlinser för att bota grön starr
Kinesiska forskare har utvecklat kontaktlinser som ska känna av om trycket i ögat stiger och därefter frigöra läkemedel för att sänka trycket vid behov. Förhoppningen är kunna bota grön starr.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
Noxious parasite forms hybrids and deceives the immune system
The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to deceive the immune system by forming new variants that are mixtures of different strains.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and Covid-19. However, not one single institute in the entire Nordic region is able to certify
-
Studie beskriver hur coronavirus trivs på olika ytor
En ny studie från KTH ökar förståelsen av hur sars-cov-2 interagerar med olika ytor på molekylär nivå.
-
Anna Törner: To kill your darlings
Förhoppningarna var höga när Anna Törner och hennes kollega startade en studie om ett kosttillskott som verkade vara overkligt bra. "Entusiastiskt drömde vi om spännande resultat och kanske en publikation i en högimpakttidskrift", skriver Anna Törner.
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, which has recently broadened its programme for leading innovators in medical research to apply
-
Paolo Macchiarini in court – “The sole intent was to cure”
Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the trial against the Italian surgeon began on Wednesday last week.
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
BREAKING